J. W. Coons Advisors LLC Has $469,000 Holdings in Hologic, Inc. (NASDAQ:HOLX)

J. W. Coons Advisors LLC cut its holdings in Hologic, Inc. (NASDAQ:HOLX) by 43.5% during the 4th quarter, HoldingsChannel reports. The fund owned 6,500 shares of the medical equipment provider’s stock after selling 5,000 shares during the quarter. J. W. Coons Advisors LLC’s holdings in Hologic were worth $469,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of HOLX. Creative Planning grew its stake in shares of Hologic by 16.6% in the third quarter. Creative Planning now owns 25,430 shares of the medical equipment provider’s stock valued at $2,072,000 after acquiring an additional 3,617 shares in the last quarter. Swedbank AB lifted its holdings in shares of Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after acquiring an additional 306,562 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in shares of Hologic by 2.4% in the third quarter. Sequoia Financial Advisors LLC now owns 7,388 shares of the medical equipment provider’s stock worth $602,000 after acquiring an additional 173 shares during the last quarter. Signaturefd LLC lifted its holdings in shares of Hologic by 13.3% in the third quarter. Signaturefd LLC now owns 2,186 shares of the medical equipment provider’s stock worth $178,000 after acquiring an additional 257 shares during the last quarter. Finally, IFM Investors Pty Ltd lifted its holdings in shares of Hologic by 2.7% in the third quarter. IFM Investors Pty Ltd now owns 56,081 shares of the medical equipment provider’s stock worth $4,568,000 after acquiring an additional 1,448 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently commented on HOLX shares. BNP Paribas raised shares of Hologic to a “strong-buy” rating in a report on Tuesday, December 10th. Leerink Partnrs lowered shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Wolfe Research initiated coverage on shares of Hologic in a report on Friday, December 13th. They issued a “peer perform” rating for the company. Raymond James reiterated an “outperform” rating and issued a $90.00 price objective (down previously from $95.00) on shares of Hologic in a report on Thursday, February 6th. Finally, UBS Group raised their price objective on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Ten research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $85.77.

Hologic Stock Up 0.2 %

Hologic stock opened at $64.47 on Monday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49. Hologic, Inc. has a 52-week low of $62.69 and a 52-week high of $84.67. The firm has a 50 day moving average price of $69.91 and a two-hundred day moving average price of $76.53. The firm has a market cap of $14.47 billion, a price-to-earnings ratio of 20.34, a PEG ratio of 2.14 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. Equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Insider Transactions at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 1.88% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.